Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Aptose Biosciences Price Performance

APTO opened at $0.38 on Wednesday. Aptose Biosciences has a 52-week low of $0.33 and a 52-week high of $2.91. The company has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.65. The company has a market cap of $6.90 million, a P/E ratio of -0.13 and a beta of 1.26.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.